
Tens of thousands of people across the globe look to Boston Scientific SCS therapy for pain relief.6

More than 70% of patients across three studies who received RFA experienced relief lasting from six to 12 months, and in some cases, years.1-3
At a single trial site in the United Kingdom conducted over a 7.5 year period, 9 out of 10 patients said they were satisfied with their therapy and 95% would recommend it to others.4
Let's take the pain quiz
Wondering if these solutions may be right for you? Take this quick quiz and find out.
References:
- MacVicar J, Borowczyk JM, MacVicar AM, Loughnan BM, Bogduk N. Cervical medial branch radiofrequency neurotomy in New Zealand. Pain Med. 2012;13(5):647-654.
- Dreyfuss P, Halbrook B, Pauza K, Joshi A, McLarty J, Bogduk N. Efficacy and validity of radiofrequency neurotomy for chronic lumbar zygapophysial joint pain. Spine. 2000;25(10):1270-1277.
- Govind J, King W, Bailey B, Bogduk N. Radiofrequency neurotomy for the treatment of third occipital headache. J Neurol Neurosurg Psychiatry. 2003;74(1):88-93.
- Thomson SJ, Kruglov D, Duarte RV. A spinal cord stimulation service review from a single centre using a single manufacturer over a 7.5 year follow-up period. Neuromodulation. 2017;20(6):589-599. N=321
- Wallace M. et al., COMBO RCT: Combination therapy with simultaneous delivery of spinal cord stimulation modalities: COMBO randomised controlled trial. Pain Manag. (2023) 13(3), 171–184.
- Boston Scientific. (2008). Spinal Cord Stimulation Position Statement. Neuromodulation Therapy Access Coalition.
Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.
Disclaimer and endnotes:
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.
Individual symptoms, situations, circumstances and results may vary. This quiz is meant for information purposes only, it is not intended to be used for medical diagnosis or treatment or as a substitute for professional medical advice. Please consult your doctor or qualified healthcare provider regarding your condition and appropriate medical treatment. This site is intended for Australian residents only. Please review the Boston Scientific Privacy Policy, for practices on the collection, storage, use and disclosure of your personal information.
Content of videos are for Information Purposes only and does not constitute medical advice. BSC strongly recommends that you consult with your physician on all matters pertaining to your health or to address any questions.
Talk to your healthcare professional about whether this product may be suitable for you as part of your overall plan to manage chronic pain. The WaveWriter Alpha System is not a first-line treatment for chronic intractable pain.
Surgery is required in order to use the WaveWriter Alpha System and any surgical procedure carries risk. Outcomes may vary for each patient. Patients should consult their healthcare professional about factors that could impact their response.
CAUTION: This product is not available for purchase by the general public. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com.
Australia and New Zealand: Boston Scientific Pty Ltd | PO Box 332 Botany NSW 1455 Australia